Other languages Celularity Inc.

Equities

CELU

US1511902041

Market Closed - Nasdaq Other stock markets 01:30:00 02/05/2024 am IST			5-day change	1st Jan Change
3.02 ^USD	-0.33%		-10.65%	+22.07%

26/03	Celularity Receives Healthcare Common Procedure Coding System Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance 3L	CI
20/03	Celularity Seeks FDA Orphan Drug Status for PDA-002 in Facioscapulohumeral Muscular Dystrophy	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Celularity Receives Healthcare Common Procedure Coding System Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance 3L	26/03
Celularity Seeks FDA Orphan Drug Status for PDA-002 in Facioscapulohumeral Muscular Dystrophy	20/03
Celularity to Execute Reverse Stock Split Next Week	24/02
Celularity Inc. Provides Sales Guidance for the First Quarter and Full Year 2024	01/02
Celularity Insider Bought Shares Worth $5,331,335, According to a Recent SEC Filing	18/01
Genting Berhad Engages in Discussions with Celularity Inc	18/01
Celularity, BioCellgraft Strike Deal for Placental-Derived Biomaterial Products	05/01
Celularity Inc. Confirms Commercialization Agreement with BioCellgraft, Inc. for Manufacture and Distribution of Advanced Biomaterial Products for Use in Oral Healthcare	04/01
Celularity Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2023	03/01
Celularity Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	03/01
Celularity Inc. Announces Resignation of Robin L. Smith, MD, from Board of Directors	30/12
Celularity Receives Non-Compliance Notice From Nasdaq	25/11
Lim Kok Thay Notifies Celularity Inc. of His Intention to Resign as a Member of the Board and All Committees	19/23/19
Celularity Inc. Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors	08/23/08
Celularity to Support Research of Regeneron's Allogeneic Cell Therapy Candidates for Solid Tumors	29/23/29
Celularity Inc Announces Multi-Year Research Collaboration Services Agreement with Regeneron Pharmaceuticals, Inc	29/23/29
Celularity Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/23/15
Celularity Inc. Announces Resignation of John Sculley as Member of the Board of Directors and All Committees	05/23/05
Celularity Inc. and Verséa Ophthalmics Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance and Biovance 3L Ocular for Ophthalmic Applications	27/23/27
Celularity Inc. to Present Data from a New Product Technology in Development for Orthopedic Applications at 7th International Conference on Orthopedics	30/23/30

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Celularity Inc.

Equities

CELU

US1511902041

Other languages

Filters